CDK9-IN-1

CAS No. 1415559-43-1

CDK9-IN-1( —— )

Catalog No. M11724 CAS No. 1415559-43-1

CDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    CDK9-IN-1
  • Note
    Research use only, not for human use.
  • Brief Description
    CDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays.
  • Description
    CDK9-IN-1 is a potent, selective CDK9 inhibitor with IC50 of 39 nM (CDK9/CycT1), >10-fold selectivity over CDK4 and >100-fold over CDK1/2/3/5/6/7, inhibits HIV-1 replication in cellular assays.
  • In Vitro
    CDK9-IN-1 is a potent CDK9 inhibitor that shows high activity against HIV-1 replication.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    Infection
  • Indication
    ——

Chemical Information

  • CAS Number
    1415559-43-1
  • Formula Weight
    499.541
  • Molecular Formula
    C26H21N5O4S
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    CC1=C(C=C(C=C1)NC2=NC=NC(=C2)C3=CC(=CC=C3)N4C(=O)C5=CC=CC=C5C4=O)NS(=O)(=O)C
  • Chemical Name
    N-(5-(6-(3-(1,3-dioxoisoindolin-2-yl)phenyl)pyrimidin-4-ylamino)-2-methylphenyl)methanesulfonamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Németh G, et al. Curr Med Chem. 2011;18(3):342-58.
molnova catalog
related products
  • Eciruciclib

    Eciruciclib is an inhibitor of CDK with antitumor properties.

  • CDK9-IN-10

    CDK9-IN-10 is a potent CDK9 inhibitor and the ligand for the PROTAC CDK9 degrader-2.

  • VMY-1-103

    A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.